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Abstract
Background: Skeletal muscle has a remarkable regenerative capacity. However, extensive damage that exceeds the
self-regenerative ability of the muscle can lead to irreversible fibrosis, scarring, and significant loss of function. Adipose-
derived stem cells (ADSC) are a highly abundant source of progenitor cells that have been previously reported to
support the regeneration of various muscle tissues, including striated muscles. The aim of this study was to evaluate
the effect of ADSC transplantation on functional skeletal muscle regeneration in an acute injury model.
Methods: Mouse ADSC were isolated from subcutaneous fat tissue and transplanted with a collagen hydrogel into the
crushed tibialis anterior muscle of mice. Recovering muscles were analyzed for gene and protein expression by real-
time quantitative polymerase chain reaction and immunohistochemistry. The muscle contractility was assessed by
myography in an organ bath system.
Results: Intramuscular transplantation of ADSC into crushed tibialis anterior muscle leads to an improved muscle
regeneration with ADSC residing in the damaged area. We did not observe ADSC differentiation into new muscle
fibers or endothelial cells. However, the ADSC-injected muscles had improved contractility in comparison with the
collagen-injected controls 28 days post-transplantation. Additionally, an increase in fiber cross-sectional size and in the
number of mature fibers with centralized nuclei was observed.
Conclusions: ADSC transplantation into acute damaged skeletal muscle significantly improves functional muscle tissue
regeneration without direct participation in muscle fiber formation. Cellular therapy with ADSC represents a novel
approach to promote skeletal muscle regeneration.
Keywords: Adipose-derived stem cells, Crush injury, Skeletal muscle regeneration, Stem cell therapy, Tissue
engineering
Background
Skeletal muscle is the most common and widely distrib-
uted tissue in the human body [1, 2] composing approxi-
mately 40% of the total body weight. Structurally, it is
built of parallel multinucleated fibers that contract upon
stimulation, generating force [3]. The ability of skeletal
muscle to regenerate is highly dependent on endogenous
paired box protein domain 7 (Pax7)-positive stem cells
called satellite cells (SC) [4, 5] which reside under the
basal lamina of each muscle fiber. Immediately upon
stress or injury, SC are activated and re-enter the cell
cycle. A small fraction of SC return to quiescent state;
however, most of them migrate to the injury site as
muscle precursor cells (MPC). MPC committed to myo-
genesis downregulate Pax7 expression and at the same
time upregulate the transcription factor myogenic differ-
entiation antigen (MyoD). They further differentiate into
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myoblasts and myofibers, restoring missing muscle mass
[6–9]. The mature myofibers express the characteristic
structural proteins like myosin heavy chain (MyHC).
This regenerative mechanism is very efficient in re-
sponse to minor injuries; however, upon large damage
the deposition of fibrotic tissue can exceed the intrinsic
regenerative capacity, leading to impaired muscle flexi-
bility and strength [10, 11]. Although there are surgical
treatment options available, in cases with major damage
the outcomes are unsatisfactory [12–14].
Several cell-based therapies have been investigated
as a possible treatment for severely damaged skeletal
muscles [15–18]. Adipose-derived stem cells (ADSC)
have received much attention within the last years, as
they are an easily accessible source of stem cells for
regenerative therapies. ADSC are mesenchymal stem
cells (MSC) that can be isolated in large quantities
from the perivascular area of subcutaneous fat tissue
by liposuction [19–22]. They are a heterogeneous
population of cells at different stages of maturation
and differentiation and have broad plasticity and dif-
ferentiation potential similar to MSC isolated from
the bone marrow (BM-MSC) [23–27]. Moreover, the
adipose tissue has a significantly higher stem cell
density than bone marrow (5% versus 0.01%) [28].
Myogenic differentiation in vitro as well as in vivo of
the ADSC has been reported so far in several studies
[29–31]. Additionally, ADSC have been shown to sup-
port tissue regeneration in a paracrine manner by se-
creting soluble factors promoting cell survival and
tissue regeneration [32, 33]. The aim of this study
was to evaluate the therapeutic potential of ADSC on
the functional recovery of skeletal muscle.
Methods
Cell isolation and culture
All the animal experiments were performed according
to Federation for Laboratory Animal Science Associa-
tions guidelines and approved by the Animal Care
Committee of the Canton Bern, Switzerland (study
no. BE 88/12).
The ADSC were isolated and cultured as described previ-
ously [34]. Briefly, the subcutaneous white fat pads were re-
moved form 7- to 8-week-old female C57BL/6 mice (Envigo,
Netherlands). Harvested fat was minced into small pieces
and digested in 0.1% collagenase type I (Sigma-Aldrich,
Buchs, Switzerland) solution at 37 °C for 1 h. The samples
were centrifuged, the supernatant containing adipocytes
was discarded, and the stromal vascular fraction pellet was
filtered (100 μm) and cultured in a growth medium
(Dulbecco’s modified Eagle’s medium (DMEM)/F12, 10%
fetal bovine serum (FBS), 1% penicillin-streptomycin (PS);
all from Gibco by Life Technologies, Carlsbad, USA).
After 24 h, the nonadherent cells were removed. Cells
were passaged at 80–90% confluency. ADSC from passage
3 were used in all experiments.
The mouse SC were isolated as described previously
[35]. Briefly, the EDL muscle was removed from the
recently euthanized C57BL/6 (females, 5 weeks old)
and digested in 0.2% collagenase I (Sigma-Aldrich) for
90 min. After digestion, the single myofibers were
transferred to matrigel matrix (Corning)-coated plates
(1:10 dilution in DMEM) and cultured in high-serum
proliferation-inducing medium containing DMEM,
20% FBS, 10% horse serum (HS), 1% PS (Gibco by
Life Technologies), 0.5% chicken embryonic extract
(CEE; US Biologicals, Salem, MA), and 10 ng/ml basic
fibroblast growth factor (bFGF; PeproTech, Rocky Hill,
NJ). SC upon activation migrate from the myofibers on
the culture dish. Cells were passaged first time after 7 days
and for every other passage at 60% confluency. To induce
differentiation, SC were placed in a low-serum medium
(DMEM, 2% HS, 4% FBS, 0.5% CEE, 1% PS).
For coculture experiments the SC were plated on
matrigel-coated dishes with a cell density of 5 × 105 cells/
cm2 in proliferation medium. After reaching 60% con-
fluency, the cells were serum starved for 24 h and then
placed in coculture with/without ADSC seeded on the
inserts (0.4 μm; Greiner Bio-One, St. Gallen, Switzerland)
in proliferation or differentiation medium. For the
ADSC-conditioned (CM-ADSC) medium, SC were cul-
tured in the same medium composition that was changed
every 24 h. After 72 h the cells were processed for real-time
quantitative polymerase chain reaction (RT-qPCR) and
Western blot (WB) analysis, and the SC in differentiation
medium were additionally stained for fiber formation with
Giemsa solution (Fluka Chemie, Buchs, Switzerland).
Flow cytometry analysis
Isolated cells were incubated with primary antibodies for
40 min at 4 °C in phosphate-buffered saline (PBS) supple-
mented with 2% FBS and 2 mM ethylenediaminetetraacetic
acid (EDTA). We used the following directly conjugated anti-
bodies: CD29 (R&D Systems), CD44 (BioLegend), CD90.2
(BioLegend), CD31 (BioLegend), CD34 (BioLegend), stem
cell antigen 1 (Sca-1; e-Bioscience), PDGFRα (BioLegend),
and PDGFRβ (BioLegend). All stainings were controlled with
appropriate isotope control antibodies. Analysis was per-
formed on a SORP LSRII (Becton Dickinson) equipped with
five lasers and data were collected with FACS DIVA soft-
ware. Analysis was performed using FlowJo™ 10.0.8 (Treestar,
Ashland, OR). All measurements were performed with three
biological replicates.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde, perme-
abilized with 0.1% Triton-X and blocked with 5% bovine
serum albumin (BSA) for 1 h. Samples were incubated
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overnight at 4 °C with the primary antibodies CD44 (BD
Pharmingen), CD29 (R&D Systems), CD90.2 (BD
Pharmingen), CD31 (Abcam, Cambridge, UK), MyHC (in
house production), Pax7 (DSHB, Iowa, USA), and MyoD
(Santa Cruz Biotechnology, Heidelberg, Germany).
Primary antibodies were detected using goat anti-rabbit or
goat anti-mouse IgG antibodies conjugated to fluorescein
isothiocyanate (FITC) or Streptavidin Alexa 594. Cells
were counterstained for F-actin with phalloidin-FITC
(Sigma-Aldrich) or phalloidin-Atto 550 and for nuclear
staining with DAPI (Sigma-Aldrich).
Cells were visualized using a fluorescence micro-
scope (Nikon Eclipse 800) or confocal laser scanning
microscope (Zeiss LSM 710; Carl Zeiss Microscopy,
Oberkochen, Germany).
For fiber formation assay the cultured myofibers were
fixed with methanol for 7 min and stained with Giemsa
solution (1:20) for 1 h at room temperature. The number
of myofibers per high-power field was calculated along
with the number of nuclei per myofiber.
Crush injury model generation
For inducing the muscle acute injury we adapted a previ-
ously described crush injury model [36, 37] with minor
changes. Thirty-nine female C57BL/6 8-week-old mice
(Envigo, Netherlands) were administered with buprenor-
phine (Temgesic®, Reckitt Benckiser, Switzerland) prior
to surgery, followed by anesthesia with 2% isoflurane
(Forene™, Abbvie) exhalation. Both lower limbs were
immobilized, and a 1.5-cm longitudinal incision of the
skin was made, exposing the tibialis anterior (TA)
muscle. The TA was separated from the tibia and under-
lying extensor digitorum longus (EDL) muscle. The
crush injury was induced on both left and right TA mus-
cles via surgical clamps (Fine Instruments, Germany).
The muscles were manually clamped twice over their
complete lengths. Immediately after the injury, the
ADSC mixed with the collagen hydrogel (Rat collagen I;
Corning), or collagen only as control, were implanted
into randomly assigned crushed muscle. For each mouse,
one TA was always implanted with ADSC and the other
TA from the same animal served as a collagen-treated
control. To track the ADSC after implantation, the cells
were labeled prior to implantation with PKH26-red
fluorescent linker (Sigma-Aldrich) according to the man-
ufacturer’s recommendations. For optical projection
tomography (OPT) analysis, the ADSC were labeled with
Cell Tracker Orange CMTMR™ dye (Thermo Fisher
Scientific) according to the manufacturer’s recommenda-
tions. A total of 3 × 106 ADSC in suspension in 50 μl
collagen hydrogel were implanted.
Morphological, histological, and functional data were
collected at 7, 14, and 28 days postinjury. The contractil-
ity of the TA muscles was measured ex vivo in an organ
bath system and healthy age- and sex-matched animals
served as controls.
Functional measurements of TA muscles
The isometric contractile measurements were performed
with the Radnoti Organ Bath System (AD Instruments)
coupled with a square pulse electrical stimulator (Grass
model S88) and data acquisition platform (AD instru-
ments Power Lab Data Acquisition System and Lab
Chart software, Oxford, UK) as described previously
[38]. Briefly, the TA muscles were dissected and fixed in
the organ bath chamber filled with 5 ml Krebs Henseleit
(Sigma-Aldrich) solution at 25 °C and oxygenated with
O2/CO2 (95%/5%). For a single twitch tension measure-
ment, the muscle was stimulated with a single 0.5-ms
square pulse at 40 Hz. The tetanus tension frequency
was established from the force-frequency relationship,
where the maximal force for the healthy muscles is
achieved at 120 Hz. The tetanus tension was induced by
stimulation with a pulse train for 300 ms at 40 V Hz.
The muscles were rested for 3 min between each series
and all the force measurements were normalized to the
weight of each individual muscle.
Analysis of TA muscle regeneration
Immunohistochemistry
TA muscles were harvested, snap frozen, and cryosec-
tioned at 7 μm. Sections were fixed with 4% paraformal-
dehyde, permabilized with 0.1% Triton-X, and blocked
with 5% BSA for 1 h. Primary antibody α-actinin (Sig-
ma-Aldrich) was detected using the M.O.M kit (Dako,
Glostrup, Denmark). The CD31 (Abcam) and Ki67
(Dako) antibodies after overnight incubation at 4 °C
were detected using goat anti-rabbit or donkey anti-goat
IgG antibodies conjugated to FITC.
Histological analysis
Cryosections were fixed with 4% paraformaldehyde and
stained for hematoxylin and eosin using standard proce-
dures. The cross-sections were visualized using a Pan-
noramic 250 Flash III slide scanner (Sysmex Suisse AG,
Horgen, Switzerland) and images were acquired using
Pannoramic Control Software (3D Histotech, Budapest,
Hungary). Myofibers diameters were determined using a
Pannoramic Viewer (3D Histotech).
Optical projection tomography
To track ADSC incorporation within the whole TA
muscle without physical sectioning we used OPT. The TA
muscles were harvested from 16 female C57BL/6
8-week-old mice (Envigo, Netherlands) and embedded in
2% ultrapure low-gelling agarose (Sigma). Samples were
dehydrated in 100% methanol (Sigma) overnight at room
temperature and then cleared in a BABB solution (benzyl
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alcohol and benzyl benzoate) for a minimum of 3 h at
room temperature. The optical sections were acquired
with Optical Projection Tomography Scanner (Bioptonics)
and analyzed with Imaris software (BitPlane, Zurich,
Switzerland).
Protein isolation and Western blotting
Total protein extracts were isolated from cells using
RIPA buffer supplemented with protease inhibitor cock-
tail (P8340 Sigma-Aldrich). The protein concentration
was determined with the BCA protein assay (Thermo
Fisher Scientific, Ecublens, Switzerland).
A total of 20 μg protein from each sample was sepa-
rated by SDS-PAGE and transferred to polyvinylidene
difluoride (PVDF) membranes (Trans-Blot Turbo,
Bio-Rad Laboratories, Cressier, Switzerland). The pri-
mary antibodies used were: alpha-actinin (Cell Signaling
Technology, Danvers, USA), MyHC (DSHB), MyoD
(Santa Cruz Biotechnology), Pax7 (Thermo Fisher), and
GAPDH (Cell Signaling). Primary antibodies were de-
tected using anti-rabbit or anti-mouse horseradish per-
oxidase (HRP)-conjugated IgG (DAKO). Signals were
visualized using enhanced chemiluminescence (Western
Lightning Plus ECL, Perkin Elmer) and developed with
CURIX 60 (AGFA). Quantification of the signal was per-
formed using ImageJ software and all the signals were
normalized to glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) expression.
RT-qPCR
Total RNA was isolated from all mouse samples and cells
using the TRIzol reagent-based method following the
manufacturer’s protocol (Life Technologies). RNA was
reverse-transcribed with the Omniscript RT Kit 200 (Qia-
gen). RT-qPCR was performed using the ABI PRISM 7900
Sequence Detection System (Applied Biosystems) accord-
ing to the standard protocols. The following mouse
TaqMan (Life Technologies) probes were used: Pax7
(Mn01354484_m1), MyoD (Mm00440387_m1), MyHC
(Mm00443013_m1), collagen type I (Coll1; Mm0048388
8_m1), transforming growth factor (TGF)b1 (Mm011788
20_m1), and GAPDH (Mm99999915_g1). Expression
levels were normalized to the expression level of the
GAPDH housekeeping gene. The experiment was re-
peated with at least three biological replicates and each
sample was analyzed in triplicate.
Statistical analysis
Statistical tests were performed using GraphPad Prism 6
software (GraphPad Prism Software Inc.). Student’s t
tests were performed for RT-qPCR analysis and WB
quantification. For the organ bath analysis, one-way ana-
lysis of variance (ANOVA) with Bonferroni correction
and paired t test were performed. For the histological
analysis of the fiber size distribution, two-way ANOVA
with multiple comparisons and Sidak corrections were
performed. p < 0.05 was considered statistically significant.
Error bars represent the mean ± standard deviation (SD).
Results
Characterization of mouse ADSC and SC
ADSC were isolated and cultured until passage 3 as a mor-
phologically homogenous population (Additional file 1:
Figure S1A). Greater than 95% of the population
expressed the MSC-specific surface markers CD29, CD44,
and CD90, and were negative for hematopoietic stem cell
CD34 and endothelial surface marker CD31 (Additional
file 1: Figure S1B). Immunocytochemistry confirmed the
surface expression of CD29, CD44, and CD90 markers, as
well as negative expression for CD31 (Additional file 1:
Figure S1C). Expression of all markers was consistent
throughout the in-vitro and in-vivo experiments. The
primary mouse SC cultured until passage 3 in the
high-serum proliferation medium exhibited a uniform, un-
differentiated morphology (Additional file 2: Figure S2A)
and were positive for Pax7 transcription factor (Additional
file 2: Figure S2B). The myogenic potential of the isolated
SC was confirmed by transferring the cells into differenti-
ation medium, where a subset of cells upregulated the
MyoD transcription factor (Additional file 2: Figure S2C)
and further formed multinucleated myotubes, positive for
the skeletal muscle-specific structural protein MyHC
(Additional file 2: Figure S2D–F).
Effect of ADSC on satellite cell activation and
differentiation in vitro
To investigate the stimulatory effect of ADSC on SC in
vitro, we compared the expression level of myogenic
markers between SC directly cocultured with ADSC ver-
sus SC cultured in the conditioned medium derived
from the ADSC (CM-ADSC). SC directly cocultured
with ADSC in proliferative medium after 72 h showed
increased mRNA and protein expression of the tran-
scription factor Pax7 (Fig. 1a, b). For SC cultured in pro-
liferative CM-ADSC the same stimulating effect on Pax7
expression was not observed (Fig. 1c). Additionally, in
proliferative medium under both culture conditions
there were no differences in MyoD expression (Fig. 1a–c).
SC cultured with ADSC in differentiation-induction medium
also did not show upregulation of MyoD or MyHC
expression in both experimental setups of direct coculture
and CM-ADSC (Fig. 1d–f). Moreover, cells cultured in
CM-ADSC demonstrated a decreased level of MyHC mRNA
expression (Fig. 1f). Additionally, for both experimental
groups cultured in differentiation-induction medium, the dis-
tribution of the average number of nuclei per myotube was
similar (Fig. 1g).
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ADSC improve skeletal muscle contractility
Immediately following a crush injury to the TA
muscle, ADSC were implanted and functional analysis
in the organ bath system was performed at days 7,
14, and 28 postinjury (Fig. 2a). From the functional
analysis, we observed a significant increase in con-
tractility for twitch and tetanus tension at 28 days for
the ADSC-treated muscles in comparison with the
collagen-treated TAs and muscles that did not receive
any treatment (Fig. 2b). Additionally, the strength of
the ADSC-treated muscles was similar to the healthy
TAs from the healthy age-matched mice. After pairing
the muscles from the same animals, ADSC-treated
muscles performed better than the collagen controls
(Fig. 2c). Moreover, we did not observe any differ-
ences in the average muscle weight between the colla-
gen- and cell-treated samples at any of the time
points; however, a significant muscle weight reduction
in the untreated group was observed at 14 and
28 days postinjury (Fig. 2d).
ADSC engraft into damaged tissue but do not contribute
to skeletal muscle formation in vivo
To elucidate the mechanisms underlying the enhanced
contractility of the ADSC-treated muscles, we tracked
the implanted cells with OPT microscopy which allowed
us to visualize the three-dimensional (3D) pattern of cell
distribution within the whole muscle (Additional file 3:
Movie S1, Additional file 4: Movie S2, Additional file 5:
Movie S3, Additional file 6: Movie S4). At 7 days postin-
jury, we observed that implanted cells colocalize with
the site of the damage, corresponding to 30% of the
whole TA volume (Fig. 3c, Additional file 4: Movie S2).
At the subsequent time points, we observed a reduction
in the number of implanted cells, as well as a decrease
in the injury size (Additional file 5: Movie S3, Additional
file 6: Movie S4; Additional file 7: Figure S4).
We also detected a fraction of ADSC aligned along
healthy myofibers at the border of the injury (Fig. 3a,
lower panel). No donor cells were found to be differenti-
ated into myofibers, fused with existing myotubes, or
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Fig. 1 Effect of adipose-derived stem cells (ADSC) on satellite cell (SC) activation and differentiation. a Relative mRNA level of paired box
protein domain 7 (Pax7) and myogenic differentiation antigen (MyoD) transcription factors in SC cocultured with/without ADSC in
proliferation-induction medium. b Protein expression of Pax7 and MyoD (upper band) transcription factors in SC cocultured with/without
ADSC in proliferation-induction medium. c Relative mRNA level of Pax7 and MyoD expressed in SC in proliferation-induction ADSC
conditioned medium (CM-ADSC). d Relative mRNA level of MyoD and MyHC in MPC cocultured in differentiation-inducing medium with/
without ADSC. e Relative protein expression of MyoD and MyHC in MPC in differentiation medium cocultured with/without ADSC and
relative mRNA levels of expression of MyoD and MyHC in a differentiation-inducing conditioned medium from ADSC. f Relative mRNA
levels of MyoD and MyHC expressed in MPC in differentiation-induction CM-ADSC. g Average number of multinucleated fibers per high-
power filed (HPF) between MPC cocultured with/without ADSC, shown as mean ± SD. The relative level of mRNA was measured using RT-
qPCR and the relative protein level was determined with Western blot. All the results were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression
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positive for the proliferation marker Ki67 (Fig. 3b) or
endothelial marker CD31 (Additional file 8: Figure S3).
ADSC treatment accelerates myoblast expansion
Seven days after the crush injury, most of the dam-
aged area was occupied by mononucleated cells, and
sporadic myofibers were present at the periphery of
the muscle (Fig. 4). By 14 days postinjury, we ob-
served a higher accumulation of myofibers and a
smaller diameter in ADSC-treated muscles. Additionally,
we detected a significantly higher number of centrally nu-
cleated immature myofibers in ADSC-treated muscles
when compared with the collagen-treated control (Fig. 4b).
At 28 days postinjury, the fraction of large myofibers
in the ADSC-treated muscles was significantly higher
than in the control samples and, at the same time, the
small myofibers were dominant in the control samples.
In both experimental groups no fibrotic tissue at 28 days
following damage was observed.
ADSC do not impact myogenesis in early regenerative
stages
Pax7 was upregulated immediately upon injury and
peaked between days 5 and 7 following damage (Fig. 5a).
This was accompanied by immediate upregulation of
MyoD during the first week postinjury, which points to
the high myogenesis. The MyHC was downregulated
within this time and was restored at later time points. In
our study, we did not observe any differences in the
expression of these early or late myogenesis markers
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between the ADSC-treated muscles and collagen-treated
controls.
The main component of the muscle extracellular matrix
(ECM), collagen type I (Coll1) was upregulated during the
entire regenerative process; however, 7 days postinjury we
observed higher collagen type I mRNA levels in the
collagen-treated controls. This observation did not correl-
ate with TGFβ1 expression (Fig. 5b).
Discussion
Developing an autologous stem cell therapy for large skel-
etal muscle injuries would be of great benefit for patients
suffering from muscle function loss due to large acute in-
juries. In regenerative medicine, ADSC are an attractive
source of easily accessible MSC with a great regenerative
potential. In this study, we demonstrated that a single
transplantation of ADSC into the crushed tibialis anterior
immediately after the injury significantly accelerates
muscle repair in mice by increasing myofiber diameter as
well as higher twitch and tetanic force generation.
ADSC-treated muscles also showed an earlier appearance
of centrally nucleated myofibers, which could explain the
greater force generation. Although the possibility of ADSC
myogenic transdifferentiation in vivo has been reported
[29, 39], in our study we did not observe direct participa-
tion of the implanted ADSC in new myofiber forma-
tion. This result points towards a possible paracrine
modulatory effect of the implanted cells, which would
be in line with the growing number of reports describing
the supportive properties of ADSC [40–43]. Unfortu-
nately, we were not able to determine the mechanism by
which the ADSC are cleared from the injured areas.
ADSC could share a similar fate as muscle-resident
fibro-adipogenic progenitors (FAPs). It was recently
shown that FAPs are activated upon injury to support the
first phase of muscle regeneration by paracrine signaling.
Once the inflammatory phase of the muscle regeneration
is finished, FAPs undergo apoptosis [44–46].
Fig. 3 Incorporation of the implanted adipose-derived stem cells (ADSC) into crushed tibialis anterior (TA) muscles. a Tracing of the PKH26 red
fluorescently labeled ADSC after 7, 14, and 28 days following cell transplantation. Frozen sections of TA muscle were counterstained for α-actinin
(green) and cell nuclei (DAPI, blue). Upper panel: scale bars = 100 μm; bottom panel: scale bars = 40 μm. b Ki67 staining showing that
fluorescently red-labeled ADSC do not proliferate after implantation. Scale bar = 40 μm. c Quantification of the ADSC reduction within the TA
muscles over time; n = 3–4 per group
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We demonstrated that ADSC have a positive stimulatory
effect on SC activation in vitro. Direct coculturing with
ADSC induces Pax7 expression in SC when compared with
conditioned medium. Therefore, the cross-talk between
these two cell populations seems to be essential for SC acti-
vation. Additionally, we found that culturing SC in
CM-ADSC leads to MyHC downregulation. This observa-
tion supports the use of stem cell implantation into the in-
jury site, where the ADSC are expected to have a higher
impact on muscle regeneration than delivering only ADSC
conditioned medium. This ex-vivo finding is inconsistent
with in-vivo studies, where it has been shown that injection
of the supernatant is sufficient for achieving a muscle regen-
eration level comparable to ADSC implantation [47, 48].
From the functional analysis of the harvested muscles,
we found that intramuscular transplantation of ADSC
into acute injured tibialis anterior muscle helps to re-
store its contractility within 28 days. There was no
indication that the implanted ADSC underwent myo-
genic or endothelial differentiation, thus suggesting a
supportive role of ADSC via paracrine and cell-cell
mechanisms. These observations are in line with pre-
vious reports, where the implantations of the ADSC
into injured muscles have shown a positive effect
[49–52]. Additionally, reduction in the weight of the
untreated muscles together with very poor functional
improvement shows the potential beneficial effect of
the collagen hydrogel itself.
Fig. 4 Adipose-derived stem cell (ADSC) treatment positively affects skeletal muscle regeneration. a Representative cross sections of TA muscles
at 7, 14, and 28 days following crush injury with ADSC or collagen transplantation. b Frequency of fiber size distribution for defined ranges of
cross-sectional diameter in TA at 14 and 28 days following crush injury with ADSC or collagen transplantation and frequency of centrally
nucleated fibers at 14 and 28 days postinjury. Results are shown as mean ± SD from n = 3–5 experimental repeats. *p < 0.05, ***p < 0.001
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One of the major causes of impaired muscle function-
ality after injury is permanent fibrotic tissue formation.
However, in this animal model we did not see connect-
ive tissue deposition at the 28-day time point in either
experimental groups. This excludes the fibrosis forma-
tion as an explanation of the functional discrepancy be-
tween the ADSC-treated muscles and the collagen
controls. Moreover, the elevated TGFβ1 expression in
the ADSC-treated muscles observed at 28 days postin-
jury was not caused by scar tissue formation. In several
studies, TGFβ1 has been described as the most import-
ant factor responsible for persistent fibrosis in skeletal
muscles [53], but mostly in chronic conditions [54, 55].
In our study, the upregulation of the TGFβ1 could be
than associated with the further ECM remodeling; how-
ever, the lack of the elevated collagen 1 expression at
28 days postinjury makes this highly unlikely.
Based on the histological assessment of the cross-sectional
areas, we concluded that the significant higher force
produced in the ADSC-treated group is an effect of a more
efficient remodeling and muscle regeneration. It has been
proven that the number and the size of the myofibers
directly correlates with the strength of the muscle
[56], and in our study the frequency distribution for
the myofibers size is shifted towards higher number
of large and centrally nucleated immature myofibers
in the ADSC-treated muscles. The work of Pecanha
et al. suggests a similar mechanism, where an injec-
tion of ADSC into lacerated soleus rat muscle results
in increased force production at 2 weeks postinjury
but not at 4 weeks, suggesting that ADSC treatment accel-
erates muscle recovery [51]. This also implies that we can-
not exclude the possibility of the full recovery of the
collagen-treated muscles at later time points.
In our in-vivo experimental setup, we did not observe
any differences in Pax7 expression between the
ADSC-treated muscles and collagen controls. This could
be due to the animal model itself, where the crush injury
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Fig. 5 Effect of adipose-derived stem cell (ADSC) transplantation on myogenesis and fibrosis in regenerating TA. a Comparative analysis of mRNA
from crushed TAs treated with ADSC or collagen hydrogel only. RT-qPCR analysis showed the expression levels of the transcription factors paired
box protein domain 7 (Pax7) and myogenic differentiation antigen (MyoD) and structural component myosin heavy chain (MyHC) over time. b
Comparative level of mRNA measured by RT-qPCR of collagen type I (Coll1) and transforming growth factor β1 (TGFβ1). All results are normalized
to GAPDH expression and plotted in relation to healthy TA expression level; n = 3–5 per group
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triggers a very high level of SC activation. Other possible
explanations are that there is an attenuated effect of the
ADSC on SC activation in vivo, or a lack of specificity in
our analysis. In our experiment, the RNA was isolated
from the site of injury. However, the crush injury activates
not only the SC in the injured area, but also SC along the
whole myofiber, which might have biased our results.
The last possibility explaining the faster functional re-
covery of the ADSC-treated muscles is their possible im-
pact on vasculogenesis. Immature myoblasts can
function and differentiate in the hypoxic condition that
is dominating at the initial phase of the muscle injury.
However, for the myoblast fusion and myotube matur-
ation the regrowth of the vasculature is essential [57]. It
has been proven in several studies that ADSC improve
the vasculature growth and new vessel formation either
by differentiation into endothelial cells or by secreting
vascular endothelial growth factor (VEGF) [31, 42, 58].
In our crush injury model we did not observe ADSC dif-
ferentiation into endothelial cells; however, based on the
recent published data showing the MSC-mediated vas-
culature repair of the damaged tissues correlating with
increased VEGF levels, we cannot exclude the hypoth-
esis that implanted ADSC support in-vivo muscle re-
generation by proangiogenic factor secretion [59–61].
However, this hypothesis needs to be further verified.
Conclusions
In the present study, we showed that ADSC therapy ac-
celerates the functional recovery of skeletal muscle in
mice. This was shown by a significant increase in both
twitch and tetanic force and an increase in the number
of large, regenerating myofibers. We did not detect any
ADSC myogenic differentiation, and therefore we sug-
gest that ADSC act via direct cell-cell or paracrine
mechanisms by secreting factors involved in transient
acceleration of skeletal muscle repair. Summarizing,
ADSC remain attractive candidates for skeletal muscle
regeneration therapies; however, further studies are ne-
cessary to fully understand their mechanisms of action.
Additional files
Additional file 1: Figure S1. Characterization of mouse primary ADSC.
(A) Isolated ADSC at passage 3 present characteristic fibroblast-like
morphology. (B) Gating strategy for flow cytometry analysis. (C) Flow
cytometry analysis shows that ADSC were positive for the MSC surface
markers CD44 (97% ± 2.2), CD90 (95.5% ± 1.5), CD29 (98.6% ± 0.7), and
PDGFRβ (57.3% ± 8.8), and negative for the hematopoietic stem cell
surface marker CD34 (0.8% ± 0.2) and endothelial surface marker CD31
(1.2% ± 0.4). Data from three independent experiments as mean ± SD. (D)
Representative immunocytochemistry confirms the expression of the se-
lected surface markers on the ADSC. (JPG 2826 kb)
Additional file 2: Figure S2. Characterization of mouse primary satellite
cells. (A) Undifferentiated SC at 60% confluency at passage 3. (B) SC are
positive for Pax7 transcription factor. (C) MPC are a fraction of SC
committed to myogenesis expressing MyoD transcription factor. (D)
Multinucleated myotubes (black arrows) formed by fusion of SC (white
arrows) at 7 days in differentiation culture conditions. (E) Fiber formation
assay demonstrating long, multinucleated myotubes. Giemsa staining at
5 days in differentiation medium. (F) Myotubes express skeletal muscle-
specific myosin heavy chain (MyHC). (JPG 3594 kb)
Additional file 3: Movie S1. Control uninjured TA. Optical projection
tomography single plane of crushed TAs with implanted ADSC. Blue:
myofibers. Red: implanted ADSC. (MP4 387 kb)
Additional file 4: Movie S2. TA crush injury 7 days. Optical projection
tomography single plane of crushed TAs with implanted ADSC. Blue:
myofibers. Red: implanted ADSC. (MP4 700 kb)
Additional file 5: Movie S3. TA crush injury 14 days. Optical projection
tomography single plane of crushed TAs with implanted ADSC. Blue:
myofibers. Red: implanted ADSC. (MP4 470 kb)
Additional file 6: Movie S4. TA crush injury 28 days. Optical projection
tomography single plane of crushed TAs with implanted ADSC. Blue:
myofibers. Red: implanted ADSC. (MP4 382 kb)
Additional file 7: Figure S4. OPT of single plane projection of the
crushed TAs with implanted ADSC and collagen treated controls at 7, 14,
and 28 days postimplantation. Blue: myofibers. Red: implanted ADSC.
(JPG 2385 kb)
Additional file 8: Figure S3. ADSC do not differentiate into endothelial
cells. Representative CD31 (green) staining showing that fluorescently
red-labeled ADSC do not overlap with the endothelial cells in the TA
muscle. Frozen sections of TA muscle were counterstained for cell nuclei
(DAPI, blue). (JPG 5130 kb)
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